Innovative approaches to immunotherapy in breast cancer

Abstract

A wide array of immunotherapies are currently in development for breast cancer. Key challenges for these therapies include the heterogeneity of breast cancers, which may require more tailored or even personalised formulations. However, the fact the breast cancers are clearly immunologically active, TNBC and Her2+ tumours in particular, highlights their potential as targets of immune-based therapies. Into the future, these approaches will be refined and rationally combined in an effort to improve outcomes for more advanced and metastatic forms of breast cancer.